Evidence map›Paper›PMID 40817077›Full record

ArticleOrphanet journal of rare diseases2025

Anti-MDA5 antibody IgG1 subtype is associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis.

Yun Wu, Yue Wang, Yulu Qiu, Chengying Lv, Yujing Zhu, Lei Wang, Lingxiao Xu, Hanxiao You, Fang Wang, Wenfeng Tan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yun WuDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Yue WangDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Yulu QiuDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Chengying LvDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Yujing ZhuDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Lei WangDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Lingxiao XuDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Hanxiao YouDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Fang WangDepartment of Cardiology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
Wenfeng TanDepartment of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China. tanwenfeng@jsph.org.cn.ORCID http://orcid.org/0000-0002-5160-2023

Funding

National Natural Science Foundation of China 81971532National Natural Science Foundation of China 82071827National Natural Science Foundation of China 82171794Science and Technology Support Program of Jiangsu Province JSDW202203
6 · The paper itself

Abstract

backgroundRapidly progressive interstitial lung disease (RP-ILD) is a severe, often fatal complication in patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis (MDA5

methodsIn a retrospective study involving 71 MDA5

resultOf the 71 patients, 30% developed RP-ILD. RP-ILD patients had a shorter disease course and a higher mortality rate than non-RP-ILD patients (both P < 0.001). A notable link was found between RP-ILD and anti-MDA5 IgG1 (P < 0.05), with 100% of RP-ILD patients showing IgG1 titers ≥ 1:100. Additionally, IgG3 positivity was more prevalent in RP-ILD (P < 0.05). Multivariate logistic regression analysis identified high titers of anti-MDA5 IgG1 and a high neutrophil-lymphocyte ratio (NLR

conclusionsElevated anti-MDA5 IgG1 titers are strongly related to RP-ILD in MDA5

Indexed as

DermatomyositisImmunoglobulin GInterferon-Induced Helicase, IFIH1Lung Diseases, InterstitialAdultAgedAutoantibodiesFemaleHumansMaleMiddle AgedRetrospective StudiesAutoantibodiesIFIH1 protein, humanImmunoglobulin GInterferon-Induced Helicase, IFIH1Anti-MDA5 antibodyIgG1Indirect immunofluorescenceRapidly progressive interstitial lung disease

Identifiers

PMID40817077
PMCPMC12357345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.